教室紹介About Us
沿革と概要
血液内科学講座は、内科学の一部門として1981年4月に開設された血液・呼吸器内科学講座（第三内科）を起源とします。初代教授である三好勇夫先生は、現在成人T細胞性白血病（ATL）として知られる白血病細胞の新培養法を考案、世界初のATL細胞株を樹立し、HTLV-Iウイルス発見に道を開きました。内科を基礎から臨床まで幅広く理解するコンセプトは、二代教授の田口博國教授へと引き継がれてゆきます。血液・呼吸器内科（第三内科）の医局員は概ね20人程度と他大学と変らないものでしたが、2010年代末には血液内科医が 2名にまで減少しました。
医学・医療上の社会的要請から 2019年に血液内科学講座が開設されました。
- 1981年
- 高知医科大学 血液・呼吸器内科学講座（第三内科）開設
- 1982年
- 三好勇夫教授就任
- 1998年
- 田口博國教授就任
- 2007年
- 横山彰仁教授就任
- 2019年
- 高知大学医学部 血液内科学講座開設
初代 小島研介教授就任
- 旧第三内科（1994年）
- 三好勇夫名誉教授と小島研介教授
.
診療
最新の医学知識と高度技術にもとづいた、高いレベルの診療を目指しています。
- 小島研介
Kensuke Kojima, MD, PhD
教授・医学博士
診療科長
日本内科学会 総合内科専門医・指導医, 日本血液学会 血液専門医・指導医, 日本造血・免疫細胞療法学会 認定医
- 吉田将平
Shohei Yoshida, MD, PhD
病院准教授・医学博士
診療副科長・病棟医長
日本内科学会 総合内科専門医・指導医, 日本血液学会 血液専門医・指導医, 日本造血・免疫細胞療法学会 認定医
- 小笠原史也
Fumiya Ogasawara, MD, PhD
助教・医学博士
医局長・外来医長
日本内科学会 総合内科専門医・指導医, 日本血液学会 血液専門医・指導医
- 渡部伸一朗
Shinichiro Watanabe, MD
医員
日本内科学会 内科専門医
- 津下典子
Noriko Tsuge, MD
医員
- 大原慶斗
Keito Ohara, MD
医員
- 津長雄太
Yuta Tsunaga, MD
医員
- 秘書室
Administrative Associate
e-mail: im82@kochi-u.ac.jp
研究・教育理念
血液疾患の基礎・臨床研究によって、原因、病態の究明から治療法の改良･開発まで、一連のシークエンスとして血液疾患を理解したいと考えています。その具体的な実績として論文業績も公開しています。医学的根拠、すなわち医学研究の成果に基づいた医療と医学教育（evidence-based-medicine）を遂行します。
In 2019, the Department of Hematology is newly established within the Kochi University, as a dynamic center for patient care, basic and translational research, and teaching in the field of benign and malignant hematology. The Department of Hematology is led by professor Kensuke Kojima, who is a respected hematologist and a pioneer in bench-to-bedside translation of novel cancer therapeutics primarily targeting p53 signaling. His research papers have been cited in >3,500 papers, mainly in the field of cancer therapeutics, suggesting a critical impact on translational research in hematology/oncology. Professor Kojima believes that case reports should add valuable information to our medical knowledge in the current era of evidence-based practice, and has continuously encouraged young physicians to write academic papers, leading to >65 published case reports. Since productive opportunities in hematology require engagement in collaborative global investigation, we are working with world-class universities and hospitals, especially with the University of Texas MD Anderson Cancer Center.
Our department originates from the third Department of Internal Medicine, which was founded in 1981. The first professor Isao Miyoshi is one of the highly respected researchers on Human T-cell leukemia virus type I (HTLV-I), which is now established as a causative agent of adult T-cell leukemia/lymphoma (ATL). The linkage between ATL and HTLV-I was proven by Dr. Miyoshi and his colleagues, demonstrating the presence of an antibody against HTLV-I in patient sera.
We continue to pursue our mission to provide state-of-the-art patient care and comprehensive education to students, trainees and hematologists through medical research, with perseverance and vigor.
Our department originates from the third Department of Internal Medicine, which was founded in 1981. The first professor Isao Miyoshi is one of the highly respected researchers on Human T-cell leukemia virus type I (HTLV-I), which is now established as a causative agent of adult T-cell leukemia/lymphoma (ATL). The linkage between ATL and HTLV-I was proven by Dr. Miyoshi and his colleagues, demonstrating the presence of an antibody against HTLV-I in patient sera.
We continue to pursue our mission to provide state-of-the-art patient care and comprehensive education to students, trainees and hematologists through medical research, with perseverance and vigor.
.
業績
高知大学血液内科（2019年〜）の業績の一部です。最新版については、ごあいさつのページをご参照ください。
英文原著（2019~. 抜粋）
1. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019; 35:721-737.
2. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019;33:2805-2816.
3. Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99:113-119.
4. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100. Blood. 2020; 36:871-884.
5. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci. 2021;112:1943-1954.
6. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 2021;35:2469-2481.
7. Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. Cancer Med. 2021;10:8976-8987.
8. Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. J Cell Mol Med. 2022;26:5580-5589.
9. Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K. COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. Intern Med. 2023 May 1;62(9):1265-1271.
10. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 investigators. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023 114:2098-2108.
11. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death Dis. 2023;14:642.
12. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9(48):eadh1436.
13. Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M*. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. Sci Rep. 2024;14:12549.
14. Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S. BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. J Clin Exp Hematop. 2025;65:174-179.
15. Kojima K, Tsuge N, Yoshida S, Umebara D, Nishida Y, Miyazaki S, Asagiri T. Myelodysplastic neoplasms with unbalanced whole-arm translocation der(5;19)(p10;q10): association with double-hit TP53 mutations. Int J Hematol. 2026;123:189-195.
16. Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY. Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study. Blood Adv. 2025;9:5954-5964.
英文総説（2019~）
Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020; 60:130-137.
英文症例報告（2019~. 抜粋）
1. Kidoguchi K, Yoshimura M, Kojima K, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. Ann Hematol. 2019;98:1305-1307.
2. Yokoo M, Kojima K, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. Ann Hematol. 2019;98:1501-1503.
3. Kidoguchi K, Kojima K, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? Int J Hematol. 2019;109:247-248.
4. Kidoguchi K, Kojima K, Yokoo M, Kimura S. BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. Ann Hematol. 2019;98:2461-2462.
5. Ogasawara F, Nakatani Y, Kojima K. Superior vena cava lymphoma. Intern Med. 2020;59:1231.
6. Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. Intern Med. 2020;59:1549-1553.
7. Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Int J Hematol. 2020;112:249-253.
8. Saeki K, Nakamura M, Kojima K. Primary pulmonary diffuse large B-cell lymphoma presenting as bulky bilateral lung tumors. Ann Hematol. 2021;100:577-578.
9. Nakamura M, Saeki K, Egashira R, Egashira Y, Kojima K. Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. Ann Hematol. 2020;99:2457-2458.
10. Nakamura M, Iwasa H, Kojima K. Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis/encephalopathy with a reversible splenial lesion. Intern Med. 2021;60:1597-1600.
11. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. Ann Hematol 2023;102:2639-2640.
12. Tsuge N, Ogasawara F, Kondo T, Yoshida S, Kojima K. A novel four-way translocation variant t(8;14;15;21)(q22;q22;q15;q22.1) in acute myeloid leukemia with RUNX1::RUNX1T1. Turk J Haematol 2024;41:128-129.
13. Kondo T, Ohara K, Yoshida S, Kojima K. Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma. Ann Hematol. 2024;103:3273-3275.
14. Yoshida S, Watanabe S, Ohara K, Iguchi M, Asagiri A, Umebara D, Kojima K. Autoimmune hemolytic anemia preceding one year before acute leukemic manifestation of lymphoma with a chronic lymphocytic leukemia immunophenotype. Int J Hematol. 2026;65:1524-1528.
15. Tsuge N, Kobayashi T, Komori M, Murakami I, Negishi T, Shigeto S, Tsunaga Y, Ohara K, Watanabe S, Yoshida S, Kojima K*. Extramedullary relapse of acute promyelocytic leukemia in the middle ear after all-trans retinoic acid combined with chemotherapy. Intern Med, in press.
16. Tsunaga Y, Iguchi M, Yoshida I, Hashimoto K, Yoshida S, Kojima K*. Spontaneous regression of pharyngeal indeterminate dendritic cell tumor with KRAS and TP53 mutations. Leuk Lymphoma, in press.
1. Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, Gronda M, Link T, Wong K, Mabanglo M, Kojima K, Borthakur G, MacLean N, Ma MCJ, Leber AB, Minden MD, Houry W, Kantarjian H, Stogniew M, Raught B, Pai EF, Schimmer AD, Andreeff M. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. 2019; 35:721-737.
2. Nii T, Prabhu VV, Ruvolo V, Madhukar N, Zhao R, Mu H, Heese L, Nishida Y, Kojima K, Garnett MJ, McDermott U, Benes CH, Charter N, Deacon S, Elemento O, Allen JE, Oster W, Stogniew M, Ishizawa J, Andreeff M. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia. 2019;33:2805-2816.
3. Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E, Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol. 2020;99:113-119.
4. Watanabe T, Yamashita S, Ureshino H, Kamachi K, Kurahashi Y, Fukuda-Kurahashi Y, Yoshida N, Hattori N, Nakamura H, Sato A, Kawaguchi A, Sueoka-Aragane N, Kojima K, Okada S, Ushijima T, Kimura S, Sueoka E. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis using the new oral demethylating agent OR-2100. Blood. 2020; 36:871-884.
5. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci. 2021;112:1943-1954.
6. Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia 2021;35:2469-2481.
7. Nishimori T, Higuchi T, Hashida Y, Ujihara T, Taniguchi A, Ogasawara F, Kitamura N, Murakami I, Kojima K, Daibata M. Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo. Cancer Med. 2021;10:8976-8987.
8. Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M. Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo. J Cell Mol Med. 2022;26:5580-5589.
9. Ogasawara F, Yoshida S, Yamane M, Takamatsu K, Arakawa Y, Nishida Y, Komatsu M, Yokoyama A, Yamagishi Y, Kojima K. COVID-19 Cluster in the Hematology/Respirology Ward of a University Hospital during the Seventh Wave of the SARS-CoV-2 Pandemic in Japan: A Descriptive Study. Intern Med. 2023 May 1;62(9):1265-1271.
10. Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 investigators. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. Cancer Sci. 2023 114:2098-2108.
11. Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A. Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Cell Death Dis. 2023;14:642.
12. Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, Ruvolo VR, Patsilevas T, Scruggs DA, Khazaei S, Mak PY, Tao W, Carter BZ, Boettcher S, Ebert BL, Daver NG, Konopleva M, Seki T, Kojima K, Andreeff M. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9(48):eadh1436.
13. Egawa Y, Higuchi T, Hashida Y, Ueno K, Kojima K, Daibata M*. Novel paired CD13-negative (MT-50.1) and CD13-positive (MT-50.4) HTLV-1-infected T-cell lines with differential regulatory T cell-like activity. Sci Rep. 2024;14:12549.
14. Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S. BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. J Clin Exp Hematop. 2025;65:174-179.
15. Kojima K, Tsuge N, Yoshida S, Umebara D, Nishida Y, Miyazaki S, Asagiri T. Myelodysplastic neoplasms with unbalanced whole-arm translocation der(5;19)(p10;q10): association with double-hit TP53 mutations. Int J Hematol. 2026;123:189-195.
16. Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY. Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study. Blood Adv. 2025;9:5954-5964.
英文総説（2019~）
Kojima K, Burger JA. Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. J Clin Exp Hematop. 2020; 60:130-137.
英文症例報告（2019~. 抜粋）
1. Kidoguchi K, Yoshimura M, Kojima K, Ureshino H, Egashira R, Yokoo M, Kai K, Egashira Y, Ohshima K, Ando T, Kimura S. Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. Ann Hematol. 2019;98:1305-1307.
2. Yokoo M, Kojima K, Sano H, Kai K, Arakawa F, Ohshima K, Matsunaga T, Kimura S. Locally distributed multicentric plasmacytomas in the ileum secondary to lymphoma chemoimmunotherapy. Ann Hematol. 2019;98:1501-1503.
3. Kidoguchi K, Kojima K, Seki R, Nagafuji K, Ohshima K, Kimura S. Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases? Int J Hematol. 2019;109:247-248.
4. Kidoguchi K, Kojima K, Yokoo M, Kimura S. BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. Ann Hematol. 2019;98:2461-2462.
5. Ogasawara F, Nakatani Y, Kojima K. Superior vena cava lymphoma. Intern Med. 2020;59:1231.
6. Fujita M, Kamachi K, Yokoo M, Kidoguchi K, Kusaba K, Kizuka-Sano H, Yamaguchi K, Nishioka A, Yoshimura M, Kubota Y, Ando T, Kojima K, Kimura S. Accelerated Phase of Atypical Chronic Myeloid Leukemia with Severe Disseminated Intravascular Coagulation at Initial Presentation. Intern Med. 2020;59:1549-1553.
7. Ando T, Sano H, Yokoo M, Kusaba K, Kidoguchi K, Yamaguchi K, Katsuya H, Yoshihara S, Kubota Y, Kojima K, Kimura S. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. Int J Hematol. 2020;112:249-253.
8. Saeki K, Nakamura M, Kojima K. Primary pulmonary diffuse large B-cell lymphoma presenting as bulky bilateral lung tumors. Ann Hematol. 2021;100:577-578.
9. Nakamura M, Saeki K, Egashira R, Egashira Y, Kojima K. Gastric emphysema in chemosensitive gastric diffuse large B cell lymphoma. Ann Hematol. 2020;99:2457-2458.
10. Nakamura M, Iwasa H, Kojima K. Central nervous system involvement in mantle cell lymphoma presenting magnetic resonance imaging features of mild encephalitis/encephalopathy with a reversible splenial lesion. Intern Med. 2021;60:1597-1600.
11. Kondo T, Iguchi M, Yoshida S, Yoshino T, Kojima K. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation. Ann Hematol 2023;102:2639-2640.
12. Tsuge N, Ogasawara F, Kondo T, Yoshida S, Kojima K. A novel four-way translocation variant t(8;14;15;21)(q22;q22;q15;q22.1) in acute myeloid leukemia with RUNX1::RUNX1T1. Turk J Haematol 2024;41:128-129.
13. Kondo T, Ohara K, Yoshida S, Kojima K. Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma. Ann Hematol. 2024;103:3273-3275.
14. Yoshida S, Watanabe S, Ohara K, Iguchi M, Asagiri A, Umebara D, Kojima K. Autoimmune hemolytic anemia preceding one year before acute leukemic manifestation of lymphoma with a chronic lymphocytic leukemia immunophenotype. Int J Hematol. 2026;65:1524-1528.
15. Tsuge N, Kobayashi T, Komori M, Murakami I, Negishi T, Shigeto S, Tsunaga Y, Ohara K, Watanabe S, Yoshida S, Kojima K*. Extramedullary relapse of acute promyelocytic leukemia in the middle ear after all-trans retinoic acid combined with chemotherapy. Intern Med, in press.
16. Tsunaga Y, Iguchi M, Yoshida I, Hashimoto K, Yoshida S, Kojima K*. Spontaneous regression of pharyngeal indeterminate dendritic cell tumor with KRAS and TP53 mutations. Leuk Lymphoma, in press.
.